ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,667.56
      0.08%
      US Tech 100
      19,264.40
      0.49%
      Dow Jones
      41,985.35
      0.08%
      Brent Oil
      71.485
      -0.50%
      Bitcoin
      85,952.10
      -0.13%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. Ecomiam SA (ALECO) Quote

      Ecomiam SA

      Ecomiam SA (ALECO)

      EU
      2.80
      0.00
      (0.00%)
      Closed March 23 12:30PM
      Delayed by 15 minutes
      Advanced chart

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      2.80
      Bid
      2.75
      Ask
      2.98
      Volume
      1,365
      2.75 Day's Range 2.80
      2.30 52 Week Range 3.36
      Market Cap
      9.433M
      Previous Close
      2.80
      Open
      2.80
      Last Trade
      490
      @
      2.8
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      1,228
      Shares Outstanding
      3,368,790
      Dividend Yield
      -
      PE Ratio
      -1.78
      Earnings Per Share (EPS)
      -1.58
      Revenue
      41.45M
      Net Profit
      -5.31M

      About Ecomiam SA

      Sector
      Frozen Specialties, Nec
      Industry
      Frozen Specialties, Nec
      Website
      www.ecomiam-bourse.com
      Headquarters
      Quimper, Finistere, Fra
      Founded
      -
      Ecomiam SA is listed in the Frozen Specialties sector of the Euronext with ticker ALECO. The last closing price for Ecomiam was 2.80 €. Over the last year, Ecomiam shares have traded in a share price range of 2.30 € to 3.36 €.

      Ecomiam currently has 3,368,790 shares outstanding. The market capitalization of Ecomiam is 9.43 € million. Ecomiam has a price to earnings ratio (PE ratio) of -1.78.

      Ask ADVFN Intelligence (AI)

      ALECO Latest News

      More News
      No news to show yet.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.15-5.084745762712.952.952.758322.80379418DE
      4-0.05-1.754385964912.853.042.7510322.91763347DE
      120.041.449275362322.763.082.4712282.86636991DE
      260.155.660377358492.653.082.317372.68031268DE
      52-0.46-14.11042944793.263.362.318532.8001252DE
      156-8.4-7511.211.281.6425454.03320314DE
      260-10.1-78.294573643412.919.751.6428768.27921245DE

      ALECO - Frequently Asked Questions (FAQ)

      What is the current Ecomiam share price?
      The current share price of Ecomiam is 2.80 €
      How many Ecomiam shares are in issue?
      Ecomiam has 3,368,790 shares in issue
      What is the market cap of Ecomiam?
      The market capitalisation of Ecomiam is EUR 9.43M
      What is the 1 year trading range for Ecomiam share price?
      Ecomiam has traded in the range of 2.30 € to 3.36 € during the past year
      What is the PE ratio of Ecomiam?
      The price to earnings ratio of Ecomiam is -1.78
      What is the cash to sales ratio of Ecomiam?
      The cash to sales ratio of Ecomiam is 0.23
      What is the reporting currency for Ecomiam?
      Ecomiam reports financial results in EUR
      What is the latest annual turnover for Ecomiam?
      The latest annual turnover of Ecomiam is EUR 41.45M
      What is the latest annual profit for Ecomiam?
      The latest annual profit of Ecomiam is EUR -5.31M
      What is the registered address of Ecomiam?
      The registered address for Ecomiam is 161 ROUTE DE BREST, QUIMPER, FINISTERE, 29000
      What is the Ecomiam website address?
      The website address for Ecomiam is www.ecomiam-bourse.com
      Which industry sector does Ecomiam operate in?
      Ecomiam operates in the FROZEN SPECIALTIES, NEC sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CLEXCumulex NV
      0.88 €
      (43.09%)
      		100
      MLOCTOctopus Biosafety
      0.134 €
      (34.00%)
      		101
      MLWEYWeya
      0.019 €
      (26.67%)
      		3.25k
      ALEUPEuroplasma
      0.0138 €
      (24.32%)
      		97.44M
      POXELPoxel
      0.22 €
      (24.29%)
      		5.01M
      ALKLAKlarsen
      0.761 €
      (-50.90%)
      		493.15k
      ALCYBCybergun
      0.0001 €
      (-50.00%)
      		68.51M
      SGDDSSpineguard DS
      0.0001 €
      (-50.00%)
      		778.85k
      DMSBSDiagnostic Medical Systems
      0.005 €
      (-50.00%)
      		3k
      HAFDSHaffner Energy DS
      0.013 €
      (-39.53%)
      		278.57k
      ATOAtos SE
      0.004 €
      (8.11%)
      		1.16B
      BCPBanco Comercial Portugues SA
      0.5448 €
      (-0.91%)
      		152.4M
      ALALOAcheterLouerFR
      0.0022 €
      (4.76%)
      		99.26M
      ALEUPEuroplasma
      0.0138 €
      (24.32%)
      		97.44M
      ALCYBCybergun
      0.0001 €
      (-50.00%)
      		68.51M

      ALECO Financials

      Financials

      Discussion

      View Full Feed
      dinogreeves dinogreeves 4 minutes ago
      All I can say is be careful what you wish for. AI is very dangerous. You see the comments from MAGA.

      https://www.youtube.com/watch?v=7wkotY0SsO4
      AZRH
      skitahoe skitahoe 4 minutes ago
      GGB,

      I've asked this question before, even if Keytruda is very effective when used with DCVax-L and it's proven in trials, how does that protect Keytruda if generic forms of it are available.

      How does a trial with Keytruda that's successful prevent someone from using D
      NWBO
      Mr. Dragon Mr. Dragon 5 minutes ago
      shyster /shi'st?r/
      noun

      An unethical, unscrupulous practitioner, especially of law. A trickish knave; one who carries on any business, especially legal business, in a mean and dishonest way. Someone who acts in a disreputable, unethical, or unscrupulous way, especially in the p
      DPLS
      3331 3331 5 minutes ago
      BIEL VA HUGE!
      https://veteranrecovery.org/
      FFFacts FFFacts 5 minutes ago
      Huh? Freak.
      HyGro HyGro 6 minutes ago
      Regulators require clinical evidence and other than GBM, NWBO has no other evidence.
      NWBO
      JoeForkeyBolo JoeForkeyBolo 6 minutes ago
      After the full MONI audit report...

      https://i.imgflip.com/9oec3j.gif
      MONI
      blackcat blackcat 7 minutes ago
      Yeah flights were way different then. I can remember flying Paris to Vancouver BC and the captain apologized that the coffee and tea service had to be stopped until the flight cleared some turbulence!
      MrMike241 MrMike241 9 minutes ago
      Bill and Hillary speaches in Berlin at the World Forum 2025 on the Future of Democracy

      https://youtu.be/23la2NKdBHo?si=0ej7fJuzdpjRM97t

      https://youtu.be/_DZ4TdjCmQc?si=5q7V7EjQuEMxICx2
      GoodGuyBill GoodGuyBill 9 minutes ago
      Much ado about nothing....

      This is what I said (as you quoted): "DCVax works, targeting all tumor-based cancers, is highly scalable, and is extensively protected by patents." Is this not true, please explain?!

      DCVax has demonstrated promising results in glioblastoma (n
      NWBO
      Almosthere Almosthere 10 minutes ago
      If the contract comes from the USA through lqmt we are outsourcing to Eontec/yihao same as Evie ring.

      Eontec cannot cancel, modify or ignore. They are being outsourced for the job.

      “Eon (via Yihao) will produce the part under the cost plus contract”

      Get i
      LQMT
      B402 B402 10 minutes ago
      Tell me about it marie....No wonder dems are at 29 and 21%........No wonder they lost, No wonder they are lost in the woods now.........

      Thanks
      wdereb79 wdereb79 10 minutes ago
      Looks like you will be able to get that 7.50 target. Congrats.
      FNMA
      downdraft downdraft 10 minutes ago
      I wonder why CEO’s don’t do back to back smaller reverse splits, so as to not shock the markets, if they really feel the need to have a better share structure or price?

      Given the situation here, with rising share accumulation the past 7 weeks, it wouldn’t bother me if I saw something
      TPTW
      Brodey79 Brodey79 11 minutes ago
      Agree 100%. It shouldn’t come as a surprise to anyone if it happens. They said so themselves in a 2023 release. There is also the possibility of delisting from otc and going ipo route. Anything is possible.
      FDCT
      manibiotech manibiotech 11 minutes ago
      Yep but they are not willing to lend them 50M under non toxic terms , to keep the lights on . Try harder
      NWBO
      Kool Aid Man Kool Aid Man 12 minutes ago
      IMO..Park's latest PR is designed to blunt the reaction when his 2024 annual report drops. It's due on Saturday (90 days after end of fiscal year)..possibly the next business day (Monday the 31st).

      As I read the following PR, Datang is the latest in his list of partners whom he clai
      SPZI
      Mr. Dragon Mr. Dragon 13 minutes ago
      The only review I'm interested in is the margin review.
      NIO
      MrMike241 MrMike241 13 minutes ago
      Jon Ossoff in Atlanta.
      https://youtu.be/sEFzw21cx7Q?si=KIMr-y38BopATH1E
      BlueChip$ BlueChip$ 14 minutes ago
      I mostly agree with that, But they will be advised to do what is needed to uplist and either they do or don't...Getting the sp to what they need is a lot easier with a 5 million float  and much more inviting to Institutional investors vs the current structure. Either way, it is what is.
      FDCT
      Buckey Buckey 14 minutes ago
      Tesla readings
      https://x.com/robinivski/status/1903829152395923708?s=46
      B402 B402 14 minutes ago
      Also fits like a glove with couple posters here, lol.....No congrats , thanks anyway. Fallacies are about the only language spoken here.....Not many honest brokers ;)
      MightyX MightyX 15 minutes ago
      It’s no-wonder TPT joined SAMENA Council for international leverage.
      TPTW
      shoondale shoondale 15 minutes ago
      Medesol Coronacide scam repeats itself at $MGON. Beware!!!!
      https://i.giphy.com/5QMOICVmXremPSa0k7.webp
      MGON
      AAPL31415926 AAPL31415926 16 minutes ago
      Gary don't sell the company short. Merck gets $25 billion per year revenue from Keytruda. I think they'd be happy to pay $25B for Nwbo to extend their patent out another 10 years and prevent anyone else from having this treatment. Not to mention all the patents and Flaskworks. And that would probab
      NWBO

      Your Recent History

      EU
      ALECO
      Ecomiam
      BOV
      PNVL3R
      DIMED ON
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads